Trial · NCT02936752
Adverse events422
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 422
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 11 | 22 | 38 |
| other | Anemia | Blood and lymphatic system disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 3 | 6 | 8 |
| other | blood in sputum | Blood and lymphatic system disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 0 | 22 | 0 |
| other | blood in sputum | Blood and lymphatic system disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 1 | 6 | 3 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 1 | 22 | 1 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 1 | 6 | 1 |
| other | Hematemesis | Blood and lymphatic system disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 1 | 22 | 1 |
| other | Hematemesis | Blood and lymphatic system disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 0 | 6 | 0 |
| other | Thrombotic thrombocytopenic purpura | Blood and lymphatic system disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 1 | 22 | 1 |
| other | Thrombotic thrombocytopenic purpura | Blood and lymphatic system disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 0 | 6 | 0 |
| other | white blood cell increased | Blood and lymphatic system disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 0 | 22 | 0 |
| other | white blood cell increased | Blood and lymphatic system disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 1 | 6 | 1 |
| other | Aortic valve disease | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 0 | 22 | 0 |
| other | Aortic valve disease | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 1 | 6 | 1 |
| other | Atrial fibrillation | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 1 | 22 | 1 |
| other | Atrial fibrillation | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 1 | 6 | 1 |
| other | Cyanosis | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 1 | 22 | 1 |
| other | Cyanosis | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 0 | 6 | 0 |
| other | Heart failure | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 1 | 0 | 22 | 0 |
| other | Heart failure | Cardiac disorders | Treatment (Entinostat, Pembrolizumab) Dose Level 2 | 1 | 6 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02936752/events